Voclosporin ophthalmic - Aurinia Pharmaceuticals

Drug Profile

Voclosporin ophthalmic - Aurinia Pharmaceuticals

Alternative Names: Luveniq; LX 211; LX 212; LX 214

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isotechnika
  • Developer Aurinia Pharmaceuticals; Lux Biosciences
  • Class Antipsoriatics; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Dry eyes
  • Discontinued Blepharitis; Uveitis

Most Recent Events

  • 27 Oct 2017 Phase I development is ongoing for Dry eyes in US (Topical) (Aurinia Pharmaceuticals pipeline, October 2017)
  • 20 Oct 2017 Aurinia plans a phase IIa trial for Dry eyes (Topical) by second quarter of 2018
  • 03 Feb 2015 Voclosporin - Lux Biosciences is available for licensing as of 03 Feb 2015. http://www.auriniapharma.com/dnn/default.aspx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top